Report

  1. Home
  2. Discounted reports

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

Market Report I 2022-10-01 I 160 Pages I Allied Market Research
Discounted by 10% to 2024-11-15

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030.Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.
The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes. Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.
The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.
KEY BENEFITS FOR STAKEHOLDERS
-The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
-It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
-A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
-The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

Key Market Segments
By Product
- Injectables
- Oral antidiabetic Drugs
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest Of Asia Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- ASTRAZENECA PLC
- BOEHRINGER INGELHEIM GMBH
- ELI LILLY AND COMPANY
- GLAXOSMITHKLINE PLC
- NOVARTIS AG
- NOVO NORDISK
- SANOFI S.A.
- TAKEDA PHARMACEUTICAL COMPANY LIMITED
- johnson and johnson md&d
- MERCK and CO., INC.

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Injectables
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Oral antidiabetic Drugs
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION
5.1 Overview
5.1.1 Market size and forecast
5.2 North America
5.2.1 Key trends and opportunities
5.2.2 North America Market size and forecast, by Product
5.2.3 North America Market size and forecast, by country
5.2.3.1 U.S.
5.2.3.1.1 Market size and forecast, by Product
5.2.3.2 Canada
5.2.3.2.1 Market size and forecast, by Product
5.2.3.3 Mexico
5.2.3.3.1 Market size and forecast, by Product
5.3 Europe
5.3.1 Key trends and opportunities
5.3.2 Europe Market size and forecast, by Product
5.3.3 Europe Market size and forecast, by country
5.3.3.1 Germany
5.3.3.1.1 Market size and forecast, by Product
5.3.3.2 France
5.3.3.2.1 Market size and forecast, by Product
5.3.3.3 United Kingdom
5.3.3.3.1 Market size and forecast, by Product
5.3.3.4 Italy
5.3.3.4.1 Market size and forecast, by Product
5.3.3.5 Spain
5.3.3.5.1 Market size and forecast, by Product
5.3.3.6 Rest of Europe
5.3.3.6.1 Market size and forecast, by Product
5.4 Asia-Pacific
5.4.1 Key trends and opportunities
5.4.2 Asia-Pacific Market size and forecast, by Product
5.4.3 Asia-Pacific Market size and forecast, by country
5.4.3.1 China
5.4.3.1.1 Market size and forecast, by Product
5.4.3.2 Japan
5.4.3.2.1 Market size and forecast, by Product
5.4.3.3 India
5.4.3.3.1 Market size and forecast, by Product
5.4.3.4 Australia
5.4.3.4.1 Market size and forecast, by Product
5.4.3.5 Rest Of Asia Pacific
5.4.3.5.1 Market size and forecast, by Product
5.5 LAMEA
5.5.1 Key trends and opportunities
5.5.2 LAMEA Market size and forecast, by Product
5.5.3 LAMEA Market size and forecast, by country
5.5.3.1 Brazil
5.5.3.1.1 Market size and forecast, by Product
5.5.3.2 Saudi Arabia
5.5.3.2.1 Market size and forecast, by Product
5.5.3.3 South Africa
5.5.3.3.1 Market size and forecast, by Product
5.5.3.4 Rest of LAMEA
5.5.3.4.1 Market size and forecast, by Product
CHAPTER 6: COMPANY LANDSCAPE
6.1. Introduction
6.2. Top winning strategies
6.3. Product Mapping of Top 10 Player
6.4. Competitive Dashboard
6.5. Competitive Heatmap
6.6. Key developments
CHAPTER 7: COMPANY PROFILES
7.1 ASTRAZENECA PLC
7.1.1 Company overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Product portfolio
7.1.5 Business performance
7.1.6 Key strategic moves and developments
7.2 BOEHRINGER INGELHEIM GMBH
7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Product portfolio
7.2.5 Business performance
7.2.6 Key strategic moves and developments
7.3 ELI LILLY AND COMPANY
7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Product portfolio
7.3.5 Business performance
7.3.6 Key strategic moves and developments
7.4 GLAXOSMITHKLINE PLC
7.4.1 Company overview
7.4.2 Company snapshot
7.4.3 Operating business segments
7.4.4 Product portfolio
7.4.5 Business performance
7.4.6 Key strategic moves and developments
7.5 NOVARTIS AG
7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Product portfolio
7.5.5 Business performance
7.5.6 Key strategic moves and developments
7.6 NOVO NORDISK
7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Product portfolio
7.6.5 Business performance
7.6.6 Key strategic moves and developments
7.7 SANOFI S.A.
7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Product portfolio
7.7.5 Business performance
7.7.6 Key strategic moves and developments
7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Product portfolio
7.8.5 Business performance
7.8.6 Key strategic moves and developments
7.9 johnson and johnson md&d
7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments
7.9.4 Product portfolio
7.9.5 Business performance
7.9.6 Key strategic moves and developments
7.10 MERCK and CO., INC.
7.10.1 Company overview
7.10.2 Company snapshot
7.10.3 Operating business segments
7.10.4 Product portfolio
7.10.5 Business performance
7.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)
TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)
TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)
TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS
TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 36.ASTRAZENECA PLC: NET SALES,
TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES
TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,
TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 46.ELI LILLY AND COMPANY: NET SALES,
TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,
TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 54.NOVARTIS AG: OPERATING SEGMENTS
TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 56.NOVARTIS AG: NET SALES,
TABLE 57.NOVARTIS AG: KEY STRATERGIES
TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT
TABLE 59.NOVO NORDISK: OPERATING SEGMENTS
TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 61.NOVO NORDISK: NET SALES,
TABLE 62.NOVO NORDISK: KEY STRATERGIES
TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT
TABLE 64.SANOFI S.A.: OPERATING SEGMENTS
TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 66.SANOFI S.A.: NET SALES,
TABLE 67.SANOFI S.A.: KEY STRATERGIES
TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,
TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 81.MERCK AND CO., INC.: NET SALES,
TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES

LIST OF FIGURES
FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION
FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030
FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)
FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020
FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
FIGURE 34. TOP WINNING STRATEGIES, BY YEAR
FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 38.COMPETITIVE DASHBOARD
FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)
FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)
FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)
FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)
FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION)

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3456.00 $3110.40
  • $5769.00 $5192.10
  • $9995.00 $8995.50
  • ADD TO BASKET
  • BUY NOW